Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus placebo survival study in moderate COPD with cardiovascular risk
2010-021638-72Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Survival. Started Mar 2011; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-021638-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021638-72.